Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Antihistamine prophylaxis for apalutamide-induced skin symptoms in metastatic hormone-sensitive prostate cancer
KCT0010743Phase 4Recruiting
- Sponsor
- Chung-Ang University Hospital
- Start
- Sep 2024
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised trial in prostate cancer (PCa) comparing Apalutamide alone with Apalutamide plus prophylactic antihistamine (2 arms). Primary endpoint: Incidence of apalutamide-related skin symptoms. Started Sep 2024; status: recruiting.
02
Drugs
apalutamideantihistamine (TDDS/ODF)
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on KCT0010743.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on KCT0010743.